Plasoron Biotech Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 16-11-2024
- Paid Up Capital ₹ 3.40 M
as on 16-11-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.63 Cr
as on 16-11-2024
- Satisfied Charges ₹ 8.63 M
as on 16-11-2024
- Revenue 35.27%
(FY 2023)
- Profit -32.17%
(FY 2023)
- Ebitda -5.19%
(FY 2023)
- Net Worth 54.94%
(FY 2023)
- Total Assets 54.89%
(FY 2023)
About Plasoron Biotech
The Corporate was formerly known as Mewell Biotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.40 M.
The company currently has active open charges totaling ₹3.63 Cr. The company has closed loans amounting to ₹8.63 M, as per Ministry of Corporate Affairs (MCA) records.
Kumar Singh and Prempal serve as directors at the Company.
- CIN/LLPIN
U51909DL2012PTC236591
- Company No.
236591
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Plasoron Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kumar Singh  | Director | 28-May-2012 | Current |
| Prempal | Director | 28-May-2012 | Current |
Financial Performance of Plasoron Biotech.
Plasoron Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.27% increase. The company also saw a substantial fall in profitability, with a 32.17% decrease in profit. The company's net worth Soared by an impressive increase of 54.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Plasoron Biotech?
In 2023, Plasoron Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹36.26 M
₹8.63 M
Charges Breakdown by Lending Institutions
- Others : 3.63 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2022 | Others | ₹3.00 Cr | Open |
| 31 Dec 2022 | Others | ₹6.26 M | Open |
| 22 Jul 2020 | State Bank Of India | ₹4.63 M | Satisfied |
| 28 Feb 2013 | Others | ₹4.00 M | Satisfied |
How Many Employees Work at Plasoron Biotech?
Plasoron Biotech has a workforce of 165 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Plasoron Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Plasoron Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
